The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hologic's revenues will increase 33.3% and EPS will grow 5.7%.
The average estimate for revenue is $626.9 million. On the bottom line, the average EPS estimate is $0.37.
Last quarter, Hologic booked revenue of $612.7 million. GAAP reported sales were 30% higher than the prior-year quarter's $471.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $0.35. GAAP EPS were -$0.19 for Q2 versus -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 61.6%, 40 basis points better than the prior-year quarter. Operating margin was 11.5%, 500 basis points worse than the prior-year quarter. Net margin was -8.3%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.54 billion. The average EPS estimate is $1.54.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 670 members out of 690 rating the stock outperform, and 20 members rating it underperform. Among 161 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 154 give Hologic a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $25.24.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.